Why the study?
Expression levels of the long noncoding RNA ANRIL between patients with stable angina and myocardial infarction had not been clarified.
Is peripheral plasma ANRIL a better diagnostic indicator than cardiac troponin I for stable angina?
Is peripheral plasma ANRIL a better diagnostic indicator than cardiac troponin I for stable angina?
Peripheral plasma ANRIL levels may serve as a novel diagnostic biomarker for stable angina, potentially outperforming traditional cardiac troponin I.
Peripheral ANRIL levels were higher in stable angina than MI; hypothesis-generating for diagnostic differentiation pending prospective validation.
INTRODUCTION: Stable angina develops during physical activity or stress, and it is typically an aspect of Coronary Heart Disease (CHD) that can lead to arrhythmia, heart failure and even sudden death. ANRIL, an Antisense Noncoding RNA gene in the INK4 Locus, is associated with multiple disorders including CHD; however, expressional levels of ANRIL in between patients with stable angina and myocardial infarction, one of the acute coronary syndrome, have not been clarified yet. METHODS: The authors enrolled 62 patients with myocardial infarction and 59 with stable angina before primary percutaneous coronary intervention, as well as 48 healthy volunteers. Their peripheral blood was collected for analysis of ANRIL and cardiac troponin I, a traditional diagnostic index of CHD by real-time PCR. RESULTS: The data showed that ANRIL is a better diagnostic indicator than cardiac troponin I in patients with stable angina and that the levels of ANRIL are higher in patients with stable angina than those with the myocardial infarction. DISCUSSION: The levels of ANRIL in peripheral plasma could be used as a good biomarker for stable angina.
No takes yet. Share an insight, caveat, or question.
Jiao et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: